Syntara Limited (PMXSF) Q4 2026 Earnings Call Transcript

SA Transcripts 161.24K Followers Follow Syntara Limited ( PMXSF ) Q4 2026 Earnings Call July 27, 2026 9:00 PM EDT Company Participants Gary Phillips - CEO, MD & Director Conference Call Participants Matthew Wright Presentation Matthew Wright Thanks for standing by, and welcome to the Syntara Investor Webinar and Q&A following the release of the company's Appendix 4C quarterly for June 2026 and other recent announcements around SNT-4728, as well as the skin scarring and myelodysplastic syndrome programs for amsulostat. There will be an initial presentation for approximately 10 or 15 minutes, after which we will take questions. If you have one you'd like to submit, please type it in using the Q&A function within Zoom, and we will get to those at the end. To kick us off, I will hand it over to CEO of Syntara, Gary Phillips. Gary Phillips CEO, MD & Director Thanks, Matt, and thank you all for joining this morning. Usual disclaimer. The June quarter. Yes, a really good quarter, actually. Sometimes when you are in the thick of things, you do not always sort of recognize what is going on. But it is actually this is a really useful point when you are sort of updating on the quarter, trying to write it up and listing the things that were progressed in that period. Reminds you of how much actually happened. In this case, at the beginning of the quarter, we had that positive FDA feedback on the clinical development pathway for amsulostat and myelofibrosis. We presented the update and the results at ASH in December last year, and this was the logical next step in presenting the full program to the FDA. We sent a full team to Washington and prepared well for the meeting. I think we lined up a good set of advisors as well